Selected research
Market Structure
Global Live Attenuated Rotavirus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Live Attenuated Rotavirus Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Live Attenuated Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Live Attenuated Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Live Attenuated Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Live Attenuated Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Live Attenuated Rotavirus Vaccine include Bharat Biotech, GSK, Lanzhou Biological Products Research Institute and Merck Sharp & Dohme, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
On the production side, the report examines Live Attenuated Rotavirus Vaccine output, growth rates, and market shares by manufacturer and by region (at regional and country level) for 2021-2026, with forecasts through 2032.
On the consumption side, the report analyzes sales of Live Attenuated Rotavirus Vaccine by region (regional and country level), company, type, and application for 2021-2026 and provides forecasts through 2032.
The report provides an overview of the global Live Attenuated Rotavirus Vaccine market in terms of capacity, output, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Live Attenuated Rotavirus Vaccine and consumption patterns in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Live Attenuated Rotavirus Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by type and application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live Attenuated Rotavirus Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
Live Attenuated Rotavirus Vaccine Segment by Company
Bharat Biotech
GSK
Lanzhou Biological Products Research Institute
Merck Sharp & Dohme
Live Attenuated Rotavirus Vaccine Segment by Type
Monovalent Vaccines
Combination Vaccines
Live Attenuated Rotavirus Vaccine Segment by Application
Hospitals and Clinics
Vaccination Sites
Live Attenuated Rotavirus Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Rotavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Rotavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Rotavirus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Live Attenuated Rotavirus Vaccine market, including product definition, global market growth prospects, production value, capacity, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Attenuated Rotavirus Vaccine industry.
Chapter 3: Detailed analysis of Live Attenuated Rotavirus Vaccine market competition landscape. Including Live Attenuated Rotavirus Vaccine manufacturers' output value, output and average price from 2021 to 2026, as well as competition analysis indicators such as origin, product type, application, merger and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 7: Production/Production Value of Live Attenuated Rotavirus Vaccine by region. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 8: Consumption of Live Attenuated Rotavirus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monovalent Vaccines
- Combination Vaccines
Applications
- Hospitals and Clinics
- Vaccination Sites
Companies covered
- Bharat Biotech
- GSK
- Lanzhou Biological Products Research Institute
- Merck Sharp & Dohme
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Live Attenuated Rotavirus Vaccine Production Value Estimates and Forecasts (2021-2032)
- 1.2.2 Global Live Attenuated Rotavirus Vaccine Production Capacity Estimates and Forecasts (2021-2032)
- 1.2.3 Global Live Attenuated Rotavirus Vaccine Production Estimates and Forecasts (2021-2032)
- 1.2.4 Global Live Attenuated Rotavirus Vaccine Market Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Global Live Attenuated Rotavirus Vaccine Market Dynamics
- 2.1 Live Attenuated Rotavirus Vaccine Industry Trends
- 2.2 Live Attenuated Rotavirus Vaccine Industry Drivers
- 2.3 Live Attenuated Rotavirus Vaccine Industry Opportunities and Challenges
- 2.4 Live Attenuated Rotavirus Vaccine Industry Restraints
3 Live Attenuated Rotavirus Vaccine Market by Manufacturers
- 3.1 Global Live Attenuated Rotavirus Vaccine Production Value by Manufacturers (2021-2026)
- 3.2 Global Live Attenuated Rotavirus Vaccine Production by Manufacturers (2021-2026)
- 3.3 Global Live Attenuated Rotavirus Vaccine Average Price by Manufacturers (2021-2026)
- 3.4 Global Live Attenuated Rotavirus Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Live Attenuated Rotavirus Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Live Attenuated Rotavirus Vaccine Manufacturers, Product Type & Application
- 3.7 Global Live Attenuated Rotavirus Vaccine Manufacturers Established Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Live Attenuated Rotavirus Vaccine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Live Attenuated Rotavirus Vaccine Players Market Share by Production Value in 2025
- 3.8.3 2025 Live Attenuated Rotavirus Vaccine Tier 1, Tier 2, and Tier 3
4 Live Attenuated Rotavirus Vaccine Market by Type
- 4.1 Live Attenuated Rotavirus Vaccine Type Introduction
- 4.1.1 Monovalent Vaccines
- 4.1.2 Combination Vaccines
- 4.2 Global Live Attenuated Rotavirus Vaccine Production by Type
- 4.2.1 Global Live Attenuated Rotavirus Vaccine Production by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Live Attenuated Rotavirus Vaccine Production by Type (2021-2032)
- 4.2.3 Global Live Attenuated Rotavirus Vaccine Production Market Share by Type (2021-2032)
- 4.3 Global Live Attenuated Rotavirus Vaccine Production Value by Type
- 4.3.1 Global Live Attenuated Rotavirus Vaccine Production Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Live Attenuated Rotavirus Vaccine Production Value by Type (2021-2032)
- 4.3.3 Global Live Attenuated Rotavirus Vaccine Production Value Market Share by Type (2021-2032)
5 Live Attenuated Rotavirus Vaccine Market by Application
- 5.1 Live Attenuated Rotavirus Vaccine Application Introduction
- 5.1.1 Hospitals and Clinics
- 5.1.2 Vaccination Sites
- 5.2 Global Live Attenuated Rotavirus Vaccine Production by Application
- 5.2.1 Global Live Attenuated Rotavirus Vaccine Production by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Live Attenuated Rotavirus Vaccine Production by Application (2021-2032)
- 5.2.3 Global Live Attenuated Rotavirus Vaccine Production Market Share by Application (2021-2032)
- 5.3 Global Live Attenuated Rotavirus Vaccine Production Value by Application
- 5.3.1 Global Live Attenuated Rotavirus Vaccine Production Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Live Attenuated Rotavirus Vaccine Production Value by Application (2021-2032)
- 5.3.3 Global Live Attenuated Rotavirus Vaccine Production Value Market Share by Application (2021-2032)
6 Company Profiles
- 6.1 Bharat Biotech
- 6.1.1 Bharat Biotech Company Information
- 6.1.2 Bharat Biotech Business Overview
- 6.1.3 Bharat Biotech Live Attenuated Rotavirus Vaccine Production, Value and Gross Margin (2021-2026)
- 6.1.4 Bharat Biotech Live Attenuated Rotavirus Vaccine Product Portfolio
- 6.1.5 Bharat Biotech Recent Developments
- 6.2 GSK
- 6.2.1 GSK Company Information
- 6.2.2 GSK Business Overview
- 6.2.3 GSK Live Attenuated Rotavirus Vaccine Production, Value and Gross Margin (2021-2026)
- 6.2.4 GSK Live Attenuated Rotavirus Vaccine Product Portfolio
- 6.2.5 GSK Recent Developments
- 6.3 Lanzhou Biological Products Research Institute
- 6.3.1 Lanzhou Biological Products Research Institute Company Information
- 6.3.2 Lanzhou Biological Products Research Institute Business Overview
- 6.3.3 Lanzhou Biological Products Research Institute Live Attenuated Rotavirus Vaccine Production, Value and Gross Margin (2021-2026)
- 6.3.4 Lanzhou Biological Products Research Institute Live Attenuated Rotavirus Vaccine Product Portfolio
- 6.3.5 Lanzhou Biological Products Research Institute Recent Developments
- 6.4 Merck Sharp & Dohme
- 6.4.1 Merck Sharp & Dohme Company Information
- 6.4.2 Merck Sharp & Dohme Business Overview
- 6.4.3 Merck Sharp & Dohme Live Attenuated Rotavirus Vaccine Production, Value and Gross Margin (2021-2026)
- 6.4.4 Merck Sharp & Dohme Live Attenuated Rotavirus Vaccine Product Portfolio
- 6.4.5 Merck Sharp & Dohme Recent Developments
7 Global Live Attenuated Rotavirus Vaccine Production by Region
- 7.1 Global Live Attenuated Rotavirus Vaccine Production by Region: 2021 VS 2025 VS 2032
- 7.2 Global Live Attenuated Rotavirus Vaccine Production by Region (2021-2032)
- 7.2.1 Global Live Attenuated Rotavirus Vaccine Production by Region (2021-2026)
- 7.2.2 Global Live Attenuated Rotavirus Vaccine Production Forecast by Region (2027-2032)
- 7.3 Global Live Attenuated Rotavirus Vaccine Production by Region: 2021 VS 2025 VS 2032
- 7.4 Global Live Attenuated Rotavirus Vaccine Production Value by Region (2021-2032)
- 7.4.1 Global Live Attenuated Rotavirus Vaccine Production Value by Region (2021-2026)
- 7.4.2 Global Live Attenuated Rotavirus Vaccine Production Value by Region (2027-2032)
- 7.5 Global Live Attenuated Rotavirus Vaccine Market Price Analysis by Region (2021-2032)
- 7.6 Regional Production Value Trends (2021-2032)
- 7.6.1 North America Live Attenuated Rotavirus Vaccine Production Value (2021-2032)
- 7.6.2 Europe Live Attenuated Rotavirus Vaccine Production Value (2021-2032)
- 7.6.3 Asia-Pacific Live Attenuated Rotavirus Vaccine Production Value (2021-2032)
- 7.6.4 South America Live Attenuated Rotavirus Vaccine Production Value (2021-2032)
- 7.6.5 Middle East & Africa Live Attenuated Rotavirus Vaccine Production Value (2021-2032)
8 Global Live Attenuated Rotavirus Vaccine Consumption by Region
- 8.1 Global Live Attenuated Rotavirus Vaccine Consumption by Region: 2021 VS 2025 VS 2032
- 8.2 Global Live Attenuated Rotavirus Vaccine Consumption by Region (2021-2032)
- 8.2.1 Global Live Attenuated Rotavirus Vaccine Consumption by Region (2021-2026)
- 8.2.2 Global Live Attenuated Rotavirus Vaccine Consumption by Region (2027-2032)
- 8.3 North America
- 8.3.1 North America Live Attenuated Rotavirus Vaccine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3.2 North America Live Attenuated Rotavirus Vaccine Consumption by Country (2021-2032)
- 8.3.3 U.S.
- 8.3.4 Canada
- 8.3.5 Mexico
- 8.4 Europe
- 8.4.1 Europe Live Attenuated Rotavirus Vaccine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.4.2 Europe Live Attenuated Rotavirus Vaccine Consumption by Country (2021-2032)
- 8.4.3 Germany
- 8.4.4 France
- 8.4.5 U.K.
- 8.4.6 Italy
- 8.4.7 Netherlands
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Live Attenuated Rotavirus Vaccine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.5.2 Asia Pacific Live Attenuated Rotavirus Vaccine Consumption by Country (2021-2032)
- 8.5.3 China
- 8.5.4 Japan
- 8.5.5 South Korea
- 8.5.6 Southeast Asia
- 8.5.7 India
- 8.5.8 Australia
- 8.6 South America
- 8.6.1 South America Live Attenuated Rotavirus Vaccine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.6.2 South America Live Attenuated Rotavirus Vaccine Consumption by Country (2021-2032)
- 8.6.3 Brazil
- 8.6.4 Argentina
- 8.6.5 Chile
- 8.6.6 Colombia
- 8.7 Middle East & Africa
- 8.7.1 Middle East & Africa Live Attenuated Rotavirus Vaccine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.7.2 Middle East & Africa Live Attenuated Rotavirus Vaccine Consumption by Country (2021-2032)
- 8.7.3 Egypt
- 8.7.4 South Africa
- 8.7.5 Israel
- 8.7.6 Türkiye
- 8.7.7 GCC Countries
9 Value Chain and Sales Channels Analysis
- 9.1 Live Attenuated Rotavirus Vaccine Value Chain Analysis
- 9.1.1 Live Attenuated Rotavirus Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Live Attenuated Rotavirus Vaccine Production Mode & Process
- 9.2 Live Attenuated Rotavirus Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Live Attenuated Rotavirus Vaccine Distributors
- 9.2.3 Live Attenuated Rotavirus Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst